<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>LMP-1, an Epstein-Barr <z:mp ids='MP_0001799'>viral</z:mp> (EBV) latency protein, is considered a <z:mp ids='MP_0001799'>viral</z:mp> oncogene because of its ability to transform rodent fibroblasts in vivo and render them tumorigenic in <z:mp ids='MP_0003815'>nude</z:mp> mice </plain></SENT>
<SENT sid="1" pm="."><plain>In human B cells, EBV LMP-1 induces DNA synthesis and abrogates <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>LMP-1 is expressed in EBV-transformed lymphoblastoid cell lines, nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp> (NPC), a subset of <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>), and in EBV-associated <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> (EBV-LPDs) </plain></SENT>
<SENT sid="3" pm="."><plain>Recently, focused deletions near the 3' end of the LMP-1 gene (del-LMP-1, amino acids 346-355), in a region functionally related to the half-life to the LMP-1 protein, have been reported frequently in human <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> virus (HIV)-associated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> (100%) and EBV+ Malaysian and Danish peripheral T-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (100%, 61% respectively), but less frequently in cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> not associated with HIV (28%, 33%) and <z:e sem="disease" ids="C0021345" disease_type="Disease or Syndrome" abbrv="">infectious mononucleosis</z:e> (33%) </plain></SENT>
<SENT sid="4" pm="."><plain>To further investigate the potential relationship of del-LMP-1 to EBV-LPDs associated with immunosuppression or <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo>, we studied 39 EBV-associated lymphoproliferations (10 benign, 29 malignant) from four distinct clinical settings: posttransplant (4 malignant, 1 reactive); HIV+ (18 malignant, 2 reactive); nonimmunodeficiency malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (ML) (7 cases); and <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> with <z:mp ids='MP_0000688'>lymphoid hyperplasia</z:mp> (7 cases) </plain></SENT>
<SENT sid="5" pm="."><plain>The presence of EBV within lymphoid cells was confirmed by EBV EBER1 <z:chebi fb="40" ids="33697">RNA</z:chebi> in situ hybridization or by polymerase chain reaction (PCR) analysis </plain></SENT>
<SENT sid="6" pm="."><plain>EBV strain type and LMP-1 deletion status were determined by PCR </plain></SENT>
<SENT sid="7" pm="."><plain>EBV strain types segregated into two distinct distributions: HIV+ (9 A; 11 B) and non-HIV (19 A, 0 B), consistent with previous reports </plain></SENT>
<SENT sid="8" pm="."><plain>Overall, del-LMP-1 were found in 1 of 5 (20%) Burkitt <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>); 17 of 24 (71%) aggressive non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (agg-NHL), and 2 of 10 (20%) reactive lymphoid proliferations </plain></SENT>
<SENT sid="9" pm="."><plain>Of the agg-NHLs, del-LMP-1 were present in 4 of 4 PT-ML (100%); 10 of 15 HIV+ ML (67%); and 3 of 5 nonimmunodeficiency malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (ML, 60%) </plain></SENT>
<SENT sid="10" pm="."><plain>A total of 2 of 7 (28%) <z:hpo ids='HP_0003745'>sporadic</z:hpo> EBV-associated <z:mp ids='MP_0000688'>lymphoid hyperplasias</z:mp> contained a del-LMP-1 </plain></SENT>
<SENT sid="11" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> del-LMP-1 were identical by DNA sequence analysis </plain></SENT>
<SENT sid="12" pm="."><plain>No correlation was identified between the presence of del-LMP-1 and the EBV strain type observed </plain></SENT>
<SENT sid="13" pm="."><plain>The high incidence of del-LMP-1 observed in agg-NHLs (71%), in contrast to the relatively low incidence observed in reactive lymphoid proliferations (28%), suggests that the deleted form may be preferentially selected in lymphomatous processes </plain></SENT>
<SENT sid="14" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> posttransplant agg-NHLs contained a del-LMP-1, and a similar frequency of del-LMP-1 was observed in both HIV-associated ML (66%) and nonimmunodeficiency ML (60%), suggesting that impairment of immune function alone is not a requirement for the expansion of malignant cells infected by EBV stains containing the deleted LMP-1 gene </plain></SENT>
</text></document>